Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.85 GBX | 0.00% | +25.42% | -72.39% |
May. 10 | Shield Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Apr. 30 | EARNINGS AND TRADING: Software Circle & Beximco report higher revenue | AN |
Sales 2024 * | 24.13M 30.55M | Sales 2025 * | 71.12M 90.02M | Capitalization | 14.47M 18.31M |
---|---|---|---|---|---|
Net income 2024 * | -18M -22.78M | Net income 2025 * | 11M 13.92M | EV / Sales 2024 * | 1.55 x |
Net Debt 2024 * | 22.98M 29.09M | Net Debt 2025 * | 20.91M 26.47M | EV / Sales 2025 * | 0.5 x |
P/E ratio 2024 * |
-0.86
x | P/E ratio 2025 * |
3.34
x | Employees | 27 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 48.78% |
Latest transcript on Shield Therapeutics plc
1 week | +25.42% | ||
Current month | +37.04% | ||
1 month | +21.31% | ||
3 months | -68.38% | ||
6 months | -69.42% | ||
Current year | -72.39% |
Managers | Title | Age | Since |
---|---|---|---|
Gregory Madison
CEO | Chief Executive Officer | 57 | 21-05-31 |
Santosh Shanbhag
DFI | Director of Finance/CFO | 47 | Jan. 15 |
David Childs
COO | Chief Operating Officer | - | 11-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 18-07-25 | |
Director/Board Member | 66 | 16-01-31 | |
Director/Board Member | 57 | 21-05-09 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 1.85 | 0.00% | 448,345 |
24-05-15 | 1.85 | -7.50% | 2,025,571 |
24-05-14 | 2 | +5.26% | 3,812,812 |
24-05-13 | 1.9 | +24.59% | 13,915,190 |
24-05-10 | 1.525 | +3.39% | 4,566,400 |
Delayed Quote London S.E., May 16, 2024 at 11:35 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-72.39% | 18.33M | |
+8.29% | 113B | |
+10.21% | 106B | |
+0.41% | 22.27B | |
-11.90% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.17% | 17.24B | |
+7.70% | 14.29B | |
+37.65% | 12.52B |
- Stock Market
- Equities
- STX Stock